|
1
|
Ruggeri L, Capanni M, Urbani E, Perruccio
K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F,
et al: Effectiveness of donor natural killer cell alloreactivity in
mismatched hematopoietic transplants. Science. 295:2097–2100. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paczulla AM, Rothfelder K, Raffel S,
Konantz M, Steinbacher J, Wang H, Tandler C, Mbarga M, Schaefer T,
Falcone M, et al: Absence of NKG2D ligands defines leukaemia stem
cells and mediates their immune evasion. Nature. 572:254–259. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sanchez-Correa B, Valhondo I, Hassouneh F,
Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés
I, Durán E, et al: DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel
immune checkpoints for natural killer cell-based cancer
immunotherapy. Cancers (Basel). 11:8772019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Long EO, Kim HS, Liu D, Peterson ME and
Rajagopalan S: Controlling natural killer cell responses:
Integration of signals for activation and inhibition. Annu Rev
Immunol. 31:227–258. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pende D, Spaggiari GM, Marcenaro S,
Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I,
Zambello R, et al: Analysis of the receptor-ligand interactions in
the natural killer-mediated lysis of freshly isolated myeloid or
lymphoblastic leukemias: Evidence for the involvement of the
poliovirus receptor (CD155) and nectin-2 (CD112). Blood.
105:2066–2073. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tahara-Hanaoka S, Shibuya K, Onoda Y,
Zhang H, Yamazaki S, Miyamoto A, Honda S, Lanier LL and Shibuya A:
Functional characterization of DNAM-1 (CD226) interaction with its
ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int Immunol.
16:533–538. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stanietsky N, Simic H, Arapovic J, Toporik
A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H, et al:
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell
cytotoxicity. Proc Natl Acad Sci USA. 106:17858–17863. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gilliland DG and Griffin JD: The roles of
FLT3 in hematopoiesis and leukemia. Blood. 100:1532–1542. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Steelman LS, Abrams SL, Whelan J, Bertrand
FE, Ludwig DE, Bäsecke J, Libra M, Stivala F, Milella M, Tafuri A,
et al: Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and
Jak/STAT pathways to leukemia. Leukemia. 22:686–707. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Daver N, Schlenk RF, Russell NH and Levis
MJ: Targeting FLT3 mutations in AML: Review of current knowledge
and evidence. Leukemia. 33:299–312. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fischer T, Stone RM, Deangelo DJ, Galinsky
I, Estey E, Lanza C, Fox E, Ehninger G, Feldman EJ, Schiller GJ, et
al: Phase IIB trial of oral Midostaurin (PKC412), the FMS-like
tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase
inhibitor, in patients with acute myeloid leukemia and high-risk
myelodysplastic syndrome with either wild-type or mutated FLT3. J
Clin Oncol. 28:4339–4345. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wander SA, Levis MJ and Fathi AT: The
evolving role of FLT3 inhibitors in acute myeloid leukemia:
Quizartinib and beyond. Ther Adv Hematol. 5:65–77. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Perl AE, Martinelli G, Cortes JE, Neubauer
A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C,
et al: Gilteritinib or chemotherapy for relapsed or refractory
FLT3-mutated AML. N Engl J Med. 381:1728–1740. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cortes JE, Khaled S, Martinelli G, Perl
AE, Ganguly S, Russell N, Krämer A, Dombret H, Hogge D, Jonas BA,
et al: Quizartinib versus salvage chemotherapy in relapsed or
refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): A
multicentre, randomised, controlled, open-label, phase 3 trial.
Lancet Oncol. 20:984–997. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu
G, Lin Q, Xu X, Leavenworth JW and Shen E: CD8+T cells
expressing both PD-1 and TIGIT but not CD226 are dysfunctional in
acute myeloid leukemia (AML) patients. Clin Immunol. 190:64–73.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cui Q, Shibata H, Oda A, Amou H, Nakano A,
Yata K, Hiasa M, Watanabe K, Nakamura S, Miki H, et al: Targeting
myeloma-osteoclast interaction with Vγ9Vδ2 T cells. Int J Hematol.
94:63–70. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Futami M, Suzuki K, Kato S, Ohmae S,
Tahara Y, Nojima M, Imai Y, Mimura T, Watanabe Y and Tojo A: The
novel multi-cytokine inhibitor TO-207 specifically inhibits
pro-inflammatory cytokine secretion in monocytes without affecting
the killing ability of CAR T cells. PLoS One. 15:e02318962020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bai Y, Soda Y, Izawa K, Tanabe T, Kang X,
Tojo A, Hoshino H, Miyoshi H, Asano S and Tani K: Effective
transduction and stable transgene expression in human blood cells
by a third-generation lentiviral vector. Gene Ther. 10:1446–1457.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cancer Genome Atlas Research Network, .
Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson A,
Hoadley K, Triche TJ Jr, Laird PW, et al: Genomic and epigenomic
landscapes of adult de novo acute myeloid leukemia. N Engl J Med.
368:2059–2074. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hirota T, Irie K, Okamoto R, Ikeda W and
Takai Y: Transcriptional activation of the mouse
Necl-5/Tage4/PVR/CD155 gene by fibroblast growth factor or
oncogenic Ras through the Raf-MEK-ERK-AP-1 pathway. Oncogene.
24:2229–2235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Quentmeier H, Reinhardt J, Zaborski M and
Drexler HG: FLT3 mutations in acute myeloid leukemia cell lines.
Leukemia. 17:120–124. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yagita M, Huang CL, Umehara H, Matsuo Y,
Tabata R, Miyake M, Konaka Y and Takatsuki K: A novel natural
killer cell line (KHYG-1) from a patient with aggressive natural
killer cell leukemia carrying a p53 point mutation. Leukemia.
14:922–930. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Deseke M and Prinz I: Ligand recognition
by the γδ TCR and discrimination between homeostasis and stress
conditions. Cell Mol Immunol. 17:914–924. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hirano M, Imai Y, Kaito Y, Murayama T,
Sato K, Ishida T, Yamamoto J, Ito T, Futami M, Ri M, et al:
Small-molecule HDAC and Akt inhibitors suppress tumor growth and
enhance immunotherapy in multiple myeloma. J Exp Clin Cancer Res.
40:1102021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Stamm H, Klingler F, Grossjohann EM,
Muschhammer J, Vettorazzi E, Heuser M, Mock U, Thol F, Vohwinkel G,
Latuske E, et al: Immune checkpoints PVR and PVRL2 are prognostic
markers in AML and their blockade represents a new therapeutic
option. Oncogene. 37:5269–5280. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tamura H, Dan K, Tamada K, Nakamura K,
Shioi Y, Hyodo H, Wang SD, Dong H, Chen L and Ogata K: Expression
of functional B7-H2 and B7.2 costimulatory molecules and their
prognostic implications in de novo acute myeloid leukemia. Clin
Cancer Res. 11:5708–5717. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dao FT, Wang J, Yang L and Qin YZ:
Development of a poor-prognostic-mutations derived immune
prognostic model for acute myeloid leukemia. Sci Rep. 11:48562021.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sallman DA, McLemore AF, Aldrich AL,
Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou HA, Eksioglu EA,
Sullivan A, et al: TP53 mutations in myelodysplastic syndromes and
secondary AML confer an immunosuppressive phenotype. Blood.
136:2812–2823. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu G, Zhang Q, Yang J, Li X, Xian L, Li
W, Lin T, Cheng J, Lin Q, Xu X, et al: Increased TIGIT expressing
NK cells with dysfunctional phenotype in AML patients correlated
with poor prognosis. Cancer Immunol Immunother. Jun 15–2021.(Epub
ahead of print).
|
|
31
|
Antar AI, Otrock ZK, Jabbour E, Mohty M
and Bazarbachi A: FLT3 inhibitors in acute myeloid leukemia: Ten
frequently asked questions. Leukemia. 34:682–696. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chu SH and Small D: Mechanisms of
resistance to FLT3 inhibitors. Drug Resist Updat. 12:8–16. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Metzelder SK, Schroeder T, Finck A, Scholl
S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, et al:
High activity of sorafenib in FLT3-ITD-positive acute myeloid
leukemia synergizes with allo-immune effects to induce sustained
responses. Leukemia. 26:2353–2359. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mathew NR, Baumgartner F, Braun L,
O'Sullivan D, Thomas S, Waterhouse M, Müller TA, Hanke K, Taromi S,
Apostolova P, et al: Sorafenib promotes graft-versus-leukemia
activity in mice and humans through IL-15 production in
FLT3-ITD-mutant leukemia cells. Nat Med. 24:282–291. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Darvin P, Toor SM, Sasidharan Nair V and
Elkord E: Immune checkpoint inhibitors: Recent progress and
potential biomarkers. Exp Mol Med. 50:1–11. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yao S and Chen L: Adaptive resistance: A
tumor strategy to evade immune attack. Eur J Immunol. 43:576–579.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qin S, Xu L, Yi M, Yu S, Wu K and Luo S:
Novel immune checkpoint targets: Moving beyond PD-1 and CTLA-4. Mol
Cancer. 18:1552019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin Z, Lan T, Zhao Y, Du J, Chen J, Lai J,
Xu L, Chen S, Zhong X, Wu X and Li Y: Higher
TIGIT+CD226-γδ T cells in patients with acute myeloid
leukemia. Immunol Invest. Aug 20–2020.(Epub ahead of print).
View Article : Google Scholar
|
